Corporate ActionJun 11, 2026, 05:26 PM
Palisade Bio Increases Authorized Shares to 450M; Appoints New Director
AI Summary
Palisade Bio stockholders approved an amendment to increase the total number of authorized shares of common stock from 300 million to 450 million shares. The company also appointed Jordan Zwick to its Board of Directors and Audit Committee, expanding the board to six members. Additionally, stockholders approved amended equity incentive and employee stock purchase plans, re-elected four directors, and ratified Baker Tilly US, LLP as the independent auditor for the fiscal year ending December 31, 2026.
Key Highlights
- Authorized common stock increased from 300,000,000 to 450,000,000 shares.
- Jordan Zwick appointed to Board of Directors and Audit Committee, expanding the board to six members.
- Mr. Zwick to receive an initial grant of restricted stock units with a grant value of $566,000.
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan.
- Stockholders approved the Amended and Restated 2021 Employee Stock Purchase Plan.
- Four directors were re-elected: J.D. Finley, Donald Williams, Emil Chuang, and Robert F. Baltera, Jr.
- Baker Tilly US, LLP was ratified as the independent registered public accounting firm for 2026.
- The Annual Meeting had a quorum of 77.59% of outstanding shares, with 129,904,054 shares present.
Price Impact
More from PALI